NCT03637387View on ClinicalTrials.gov

802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia

PHASE3WithdrawnINTERVENTIONAL

0

Timeline

Start Date

March 1, 2023

Primary Completion Date

August 18, 2025

Study Completion Date

September 29, 2026

Conditions

Trigeminal Neuralgia

Interventions

DRUG

BIIB074

Administered as specified in the treatment arm

DRUG

Placebo

Administered as specified in the treatment arm.

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Biogen

INDUSTRY